2. Search Result
Search Result
Results for "

ERF

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

5

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150090
    SRI-41315
    1 Publications Verification

    		 CFTR Inflammation/Immunology
    SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity .
    SRI-41315
  • HY-RS04488
    ERF Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    ERF Human Pre-designed siRNA Set A contains three designed siRNAs for ERF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ERF Human Pre-designed siRNA Set A
    ERF Human Pre-designed siRNA Set A
  • HY-163938A
    PROTAC erf3a Degrader-2

    		PROTACs Cancer
    PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: E3 ligase ligand (HY-W763812)) .
    PROTAC erf3a Degrader-2
  • HY-163938
    PROTAC erf3a Degrader-1

    		PROTACs Cancer
    PROTAC erf3a Degrader-1 (Compound C63) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-1 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-1 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: CRBN ligand (HY-41547)) .
    PROTAC erf3a Degrader-1
  • HY-153176
    PAT-IN-1

    		Ras Cancer
    PAT-IN-1 is a protein acyl transferases (PAT) inhibitor. PAT-IN-1 competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) .
    PAT-IN-1
  • HY-153177
    PAT-IN-2

    		Ras Cancer
    PAT-IN-2 is a protein acyl transferases (PAT) inhibitor. PAT-IN-2 competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 25) .
    PAT-IN-2
  • HY-163960
    NH2-Ph-NH-cyclohexane-NH-Boc

    		PROTAC Linkers Cancer
    NH2-Ph-NH-cyclohexane-NH-Boc is a PROTAC linker. NH2-Ph-NH-cyclohexane-NH-Boc can be used in synthesis PROTAC erf3a Degrader-1 (HY-163938) .
    NH2-Ph-NH-cyclohexane-NH-Boc
  • HY-163961A
    Thalidomide-NH-cyclohexane-NH-Ph-NH2

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-NH-cyclohexane-NH-Ph-NH2 is an E3 Ligase Ligand-Linker Conjugate. Thalidomide-NH-cyclohexane-NH-Ph-NH2 can be used to synthesize PROTAC erf3a Degrader-2 (HY-163938A) .
    Thalidomide-NH-cyclohexane-NH-Ph-NH2
  • HY-120743
    Triplin

    		Biochemical Assay Reagents Metabolic Disease
    Triplin is a copper chelator, Triplin perturbs copper ion transport involved in the interaction of RAN1 and ATX1. Triplin suppresses the toxic effects of excess copper ions on plant root growth. Triplin increases the RNA expression of ERF1. Triplin acts through the ethylene signal transduction pathway. Triplin also is a bacterial pore-former .
    Triplin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: